Junshi is a pharmaceutical company that specializes in the research, development, and production of innovative and effective medicines. Their products cater to various disease areas, aiming to improve the overall health and well-being of individuals.
Incorporated in 2001
Headquartered in Shanghai, China
Initially focused on developing therapies for infectious diseases and cancer
Expanded research areas to include autoimmune diseases and metabolic disorders
Received regulatory approvals for several products in China
Established strategic collaborations with global pharmaceutical companies
A pharmaceutical company specializing in the development of innovative treatments for diabetes and related metabolic disorders.
A biopharmaceutical company engaged in the discovery, development, and commercialization of high-quality biologics for the treatment of cancer.
A pharmaceutical company focused on the research, development, and commercialization of innovative medicines for cardiovascular, respiratory, and central nervous system disorders.
An innovative monoclonal antibody for the treatment of various types of cancer, including melanoma and nasopharyngeal carcinoma.
A levodopa prodrug used in the treatment of Parkinson's disease, offering improved efficacy and reduced side effects compared to conventional levodopa formulations.
A monoclonal antibody designed for the treatment of COVID-19, targeting the spike protein of the SARS-CoV-2 virus.
Junshi develops products for various disease areas, including cancer, autoimmune diseases, metabolic disorders, and infectious diseases.
Junshi is headquartered in Shanghai, China.
Junshi's research primarily focuses on the development of innovative therapies for cancer and infectious diseases, along with a growing interest in autoimmune diseases and metabolic disorders.
Yes, Junshi has established strategic collaborations with global pharmaceutical companies to advance their research, development, and commercialization efforts.
Junshi's notable product for cancer treatment is Toripalimab, an innovative monoclonal antibody used in the treatment of various types of cancer.